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Edited by Lukas HuberAbstract Atrial ﬁbrillation (AF), the most common cardiac
arrhythmia, is frequently accompanied by atrial interstitial ﬁbro-
sis. Angiotensin II (Ang II) dependent signaling pathways have
been implicated in interstitial ﬁbrosis during the development of
AF. However, Ang II could be further degraded by angiotensin
converting enzyme II (ACE2). We examined expression of
ACE2 in the ﬁbrillating atria of pigs and its involvement in ﬁbrotic
pathogenesis during AF. Nine adult pigs underwent continuous
rapid atrial pacing to induce sustained AF and six pigs were sham
controls (i.e., sinus rhythm; SR). In the histological examinations,
extensive accumulation of extracellular matrix in the interstitial
space of the atria, as evidenced by Masson’s trichrome stain, were
found in ﬁbrillating atria. The relative amount of collagen type I in
the atria with AF was signiﬁcantly increased as compared with
that in the SR. Local ACE activity in the ﬁbrillating atria was also
markedly higher than that in the SR subjects. ACE2 gene and pro-
tein expression in the AF subjects were signiﬁcantly decreased
compared with those in the SR subjects, whereas expression of
mitogen-activated/ERK kinase 1/2 (MEK1/2), extracellular sig-
nal-regulated protein kinase 2 (ERK2), and activated ERK2 were
signiﬁcantly greater in the AF subjects. We propose that decreas-
ing ACE2 expression during AF may aﬀect the Ang II-dependent
signaling pathway. In addition, our results suggest that atrial
ﬁbrosis in AF may be induced by antagonistic regulation between
ACE and ACE2 expression.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Atrial ﬁbrillation (AF) is the most common arrhythmia in
clinical practice. Several studies have shown that AF causesAbbreviations: ACE, angiotensin converting enzyme; ACE2, angioten-
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infarction; RAS, renin-angiotensin system; SR, sinus rhythm
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accompanied by hypertrophic growth of cardiac myocytes
and hyperplastic growth of cardiac ﬁbroblasts and results in
increased deposition of extracellular matrix (ECM) constitu-
ents leading to ﬁbrosis [4]. Likewise, Li et al. [5] have shown
in a heart failure model that AF can be promoted by atrial
ﬁbrosis that interferes with local conduction. Furthermore,
atrial ﬁbrosis alone is enough to promote AF occurrence is
proved in animal model [2,6]. Several studies revealed that
the renin-angiotensin system (RAS) is associated with the
development of AF [7–10]. The cardiac eﬀects of prolonged
stimulation of angiotensin II (Ang II), an important eﬀector
peptide in the RAS, have been well documented and include
the accumulation of interstitial ﬁbrosis [11].
Angiotensin I (Ang I) is converted to Ang II by angiotensin
converting enzyme (ACE), an important regulator of the RAS
[12]. About 90% of patients with AF have clinical or subclini-
cal cardiovascular disease that may alter cardiac pressure and
volume load [13]. These can lead to myocardial stretch, which
is a potent stimulus that increases local Ang II levels [14,15].
Yamazaki et al. [15] showed that mechanical stretch can induce
cardiac hypertrophy by Ang II-dependent mechanisms by acti-
vation of the extracellular signal-regulated kinase (ERK)-mito-
gen activated protein kinase (MAPK) pathway. Activation of
the ERK pathway by G protein–coupled receptor agonists,
such as Ang II, can induce cellular diﬀerentiation processes
and activation of ﬁbroblasts that cause the development of
interstitial ﬁbrosis [16,17]. Ang II can also induce proliferation
of ﬁbroblasts and accumulation of ECM proteins via activa-
tion of ERK1/ERK2, members of a MAPK subfamily
[18,19]. Furthermore, inhibitions of the generation or action
of Ang II in atrial tissue can downregulate ERK1 and ERK2
expression, resulting in reduced ﬁbrosis [20]. Enhanced activa-
tion of ERK1/ERK2 within interstitial heart cells, most likely
due to activated RAS, may explain the presence of marked at-
rial ﬁbrosis in association with AF [9].
In addition to being a potent vasopressor, Ang II also medi-
ates a broad array of physiological and pathophysiological ef-
fects by binding to speciﬁc cell membrane receptors [21,22].
Human studies have demonstrated that the angiotensin II type
1 (AT1) receptors is largely responsible for many of the path-
ological eﬀects of Ang II, inclusive of marked cardiac ﬁbrosis
[23]. Activation of AT1 receptor, which occurs in the atria with
increased frequency in patients with AF, induces ﬁbrosis,
which promotes the occurrence of arrhythmia [24]. Several
studies has shown that AT1 receptor antagonists could reallyation of European Biochemical Societies.
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tural remodeling, a contributing factor for the development
of AF, in animal model or clinical trial [10,25–27].
Angiotensin converting enzyme II (ACE2), an enzyme iden-
tiﬁed in rodent and human with a more restricted distribution
than ACE, is expressed mainly in heart and kidney [28,29].
ACE2 cleaves a single residue from Ang I to generate angio-
tensin 1–9 (Ang 1–9) and cleaves Ang II, the main eﬀector of
the RAS, to the vasodilator angiotensin 1–7 (Ang 1–7)
[28,29]. Results from experiments with ace2 mutant mice sug-
gest that ACE2 negatively regulates activated RAS [28–30].
Thus, ACE2 may have an important role in ﬁbrotic forma-
tion during AF. However, regulation of ACE2 in ﬁbrillating
atrium is largely unexplored. Therefore, the purpose of this
study was to determine ACE2 expression in pace-inducing
ﬁbrillating atria and to test the hypothesis that downregulated
ACE2 in the atria is associated with AF.2. Materials and methods
2.1. Materials
Anti-ERK2 (#sc154), anti-phospho-ERK2 (#sc7976), and anti-ACE2
(#sc17719) antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-phospho-MEK1/2 (#9121) antibody was pur-
chased from Cell Signaling Technology (Danvers, MA). Antibodies
against b-actin (#ac15) and collagen type I (#ab6308) were purchased
from Abcam (Cambridge, MA). HRP-labeled secondary antibodies
against goat IgG (#sc2020), mouse IgG (#sc2005), and rabbit IgG
(#sc2004) were purchased from Santa Cruz Biotechnology. All other
reagents were purchased from Sigma–Aldrich (Poole, Dorset, UK).
2.2. Experimental model
Fifteen female pigs (average weight of 65 kg) were used. Of these, six
were sham controls that were kept in sinus rhythm (SR), while the
remaining nine pigs were subjected to experimentally induce sustained
AF as described in our previous report [31,32]. In brief, Yorkshire–
Landrace pigs were treated with intravenous anesthesia by thiamylal
(2–3 mg/kg) (Kyorin Pharmaceutical, Tokyo, Japan) and then transve-
nously implanted with a high-speed pacemaker (Itrel-III, model 7425;
Medtronic, Minneapolis, MN). A screw-in atrial lead (Model 4568;
Medtronic) was positioned at the right atrial appendage via the left
internal jugular vein under ﬂuoroscopy. The pacemaker was set to pace
the atria at a rate of 400–600 beats per minute in the AF group. During
the period of atrial pacing, oral digoxin (0.25 mg per day) was given
daily to minimize the possibility of developing congestive heart failure.
Consistency of the atrial pacing was checked daily in the ﬁrst week and
weekly thereafter with a portable ECG monitor by a programmer turn-
ing the atrial pacing on and oﬀ. After 4–6 weeks of continuous pacing,
the pigs exhibited sustained AF (i.e., AF was maintained P 24 h after
discontinuance of atrial pacing). In the SR control group, the pigs re-
ceived a sham operation of pacemaker implantation without atrial pac-
ing for 4 weeks. The pigs of AF and SR group were euthanized by
high-dose intravenous barbiturate, the atrial pacemaker was removed
and the animals were sacriﬁced for atrial tissue sampling. The experi-
mental protocol conformed to the Guide for the Care and Use of Lab-
oratory Animals (NIH Publication No. 85–23, revised 1996) and was
approved by the animal welfare committees of the National Chiao
Tung University and the National Taiwan University. All pigs were
provided by the Animal Technology Institute Taiwan (ATIT) and
housed at the animal facility at ATIT.2.3. Tissue sampling and treatments
The left atrial appendages were excised from the isolated hearts and
trimmed for pathological examination and frozen storage according to
the protocol of our previous report [33]. For assays of ACE activity,
RT-PCR and Western blotting, the excised specimens were immedi-
ately frozen in liquid nitrogen and stored at 80 C until use for
RNA or protein extraction. For pathological examination, the tissues
were cut into small blocks about 10 · 5 mm and immersed in 4% phos-phate-buﬀered formalin for 24 h. After dehydration, each section was
cut into 5 lm-thick slices. Deparaﬃnized sections were stained with
Masson’s trichrome.
2.4. ACE activity assay
Atrial tissues were frozen immediately after collection and kept at
80 C until use. Atrial tissues were minced in homogenization buﬀer
consisting of 50 mM HEPES (pH 7.4), 0.3 M NaCl and 1 lM ZnCl,
and homogenized at maximum speed for 30 s. Tissue homogenates
were centrifuged at 3000·g for 10 min. The supernatant was then sub-
jected to centrifugation at 14000·g for 60 min at 4 C. The resulting
membrane pellet was resuspended in the homogenization buﬀer con-
taining 0.5% Triton X-100 and stored overnight at 4 C. After addi-
tional centrifugation at 14000·g for 30 min, the supernatant was
collected and used as the source of tissue ACE. Protein concentration
was determined by the Bradford’s method using bovine serum albumin
(BSA) as a standard.
ACE activity was measured by the method of Cushman with slight
modiﬁcation [34]. Brieﬂy, 60 ll of 0.4 mM hippuryl-histidyl-leucine
(HHL) as substrate was added to 10 ll of sample (30 lg protein) and
incubated at 37 C for 30 min with continuous agitation at 450 rpm.
HHL was prepared in 100 mM borate buﬀer (pH 8.3) containing
0.3 M NaCl. The reaction was stopped by heating at 65 C for
15 min, and then was centrifuged at 12000·g for 5 min, and then
10 ll of supernatant was injected into the column, and the amount of
hippuric acid (HA) liberated from the substrate was analyzed by high
performance liquid chromatography (HPLC). One unit of ACE activity
is deﬁned as the amount of enzyme catalyzing the release of 1 lMofHA
from HHL per minute at 37 C under standard assay condition.
HPLC was performed on a Waters (Milford, MA) Alliance HPLC
system equipped with a 2996 photodiode array detector and Waters
717 plus autosampler. Separations were accomplished on Waters
Atlantis dC18 column (4.6 mm · 250 mm, 5 lm). The HPLC separa-
tion of HHL and HA was detected at 228 nm. The column was eluted
(0.5 ml/min) with a two solvent system: (A) 0.05% triﬂuoroacetic acid
(TFA) in water and (B) 0.05% TFA in acetonitrile (45%) for 20 min.
External standard HA samples were prepared freshly on a daily basis
and used for calculation of the concentration of HA.
2.5. Protein extraction and electrophoresis
Frozen atrial tissues (about 0.2 g) were homogenized in 1 ml of ice-
cold lysis buﬀer containing 20 mM Tris–HCl, 1 mM dithiothreitol,
200 mM sucrose, 1 mM EDTA, 0.1 mM sodium orthovanadate,
10 mM sodium ﬂuoride, 0.5 mM PMSF, and 1% (v/v) Triton X-100.
The homogenate was then centrifuged at 12000·g at 4 C for
10 min, and the supernatant was collected for sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE). Protein concen-
tration was determined by the Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA) with BSA as a standard. Aliquots containing 30 lg pro-
tein were resolved on 10% slab SDS–PAGE gels.
2.6. Western blotting
Protein extracts of the left atrial appendages separated by SDS–
PAGE were electrophoretically transferred to PVDF membranes
(Immobilon-P; Millipore, Bedford, MA). Brieﬂy, non-speciﬁc bind-
ing sites were blocked by incubating membranes in 5% non-fat milk.
Primary antibodies against proteins were diluted as follows: 1:5000
for b-actin, 1:1000 for ACE2, ERK2, phosphorylated ERK2 and phos-
phorylated MEK1/2, and 1:2000 for collagen I. The secondary anti-
body was applied using a dilution of 1:2000. Substrates were
visualized using ECL according to the manufacturer’s instructions
(Western Lightning Chemiluminescence Reagent Plus; Perkin–El-
mer, Boston, MA) and by exposing the membranes to X-Ray ﬁlm
(Super Rx Medical X-Ray Film; Fujiﬁlm, Kanagawa, Japan). The
bands were detected at the expected size. The band intensity was quan-
tiﬁed using densitometric analysis by imaging software (Scion image;
Scion, Frederick, MD). The amounts of collagen I, ACE2, ERK2,
phosphorylated ERK2, and phosphorylated MEK1/2 are expressed
relative to the amount of b-actin in respective samples.2.7. RNA isolation
Total cellular RNA of the left atrial appendages was extracted as
recommended by the manufacturer of TRIzol (GIBCO BRL, Rock-
ville, MD). Brieﬂy, the TRIzol method consists of the addition of 1 ml
Table 1
Sequences of the primers used in this study for RT-PCR analysis
Gene GenBank accession number Forward/Reverse sequence (5 0 ﬁ 3 0) Condition (cycle no.) Size of PCR product (bp)
ACE2 AY623811 CAT GAT GAA ACA TAC TGT GAC C 94 C, 30 sﬁ 55 C, 30 sﬁ 72 C, 412
CTC CAA GAG CTG ATT TTA GG 45 s (32)
ERK2 M84489 CAG ACA TGA GAA CAT CAT TGG 94 C, 30 sﬁ 55 C, 30 sﬁ 72 C, 622
TTT GGA GTC AGC ATT TGG 45 s (32)
GAPDH BC059110 GGT GAT GCT GGT GCT GAG TA 94 C, 30 sﬁ 55 C, 30 sﬁ 72 C, 413
TTC AGC TCT GGG ATG ACC TT 45 s (24)
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mixture was vigorously agitated for 30 s and incubated at room tem-
perature for 5 min. After this procedure, 200 ll chloroform was added
to the tube, and the solution was centrifuged at 12000·g for 15 min.
The aqueous phase was transferred to a clean tube, precipitated with
500 ll isopropyl alcohol, and centrifuged at 12000·g for 15 min. The
resulting RNA pellet was then washed with 1 ml of 75% cold ethanol
and centrifuged at 7500·g at 4 C for 5 min. The pellet was dried at
room temperature, resuspended in 20 ll of diethylpyrocarbonate
(DEPC)-treated water, and stored at 80 C. RNA was quantiﬁed
by measuring absorbance at 260 nm and 280 nm and electrophoresed
on a denaturing 1% agarose gel. The integrity and relative amounts
of RNA were evaluated using ultraviolet visualization of ethidium bro-
mide-stained RNA.
2.8. RT-PCR
Semi-quantitative RT-PCR was performed as our previously re-
ported [35]. For cDNA synthesis, 3 lg RNA was supplemented in a
total reaction volume of 20 ll with 1· reverse transcription (RT) buf-
fer, 0.5 mM dNTPs, 2.5 lM oligo-dT (Invitrogen, Carlsbad, CA),
40 U/ll RNase inhibitor (Invitrogen), and 20 U/ll Superscript II
reverse transcriptase (Invitrogen). After incubation for 60 min at
50 C, the mixture was incubated for 15 min at 70 C to denature the
products. The mixture was then chilled on ice.
PCR primers for RT-PCR analysis were shown in Table 1. PCR
reaction contains 2 ll cDNA, 1 ll each primer (10 lM), 5 ll of 10·
PCR buﬀer, 2 ll of 10 mM dNTP, 1 ll of 5 U/ll Taq polymerase (Pro-
mega, Madison, WI) and 38 ll distilled water in a total volume of
50 ll. Thermal cycler (MiniCycler; MJ Research, Waltham, MA)
conditions were as follows: 1 cycle of 5 min at 94 C, 24 or 32 cycles
of denaturation at 94 C for 30 s, annealing at 55 C for 30 s, and elon-
gation at 72 C for 45 s, and 1 cycle of 3 min at 72 C. The resulting
PCR products were visualized on 2% agarose gels stained with ethi-
dium bromide. The stained image was recorded by an image analyzer
(Kodak DC290 Digital camera System; Eastman Kodak, Rochester,
NY), and the band intensity was quantiﬁed using densitometric analy-
sis by Scion image. The relative mRNA expression of the ACE2 and
ERK2 genes was calculated as ratios to glyceraldehyde-3-phophate
dehydrogenase (GAPDH) expression.
2.9. Statistical analysis
All values are expressed as means ± standard deviation (S.D.). A
Student’s t-test was used to evaluate diﬀerences between groups of dis-
crete variables. A value of P < 0.05 was considered statistically signif-
icant.3. Results
Nine pigs with sustained AF were examined for electrophys-
iological properties and histological characteristics as de-
scribed in our previous reports [31,32]. In the histological
examinations, enlarged intracellular spaces and extensive accu-
mulation of ECM in the interstitial space of the atria, as evi-
denced by Masson’s trichrome stain, were found in
ﬁbrillating atria (Fig. 1A and B). Expression of collagen I, a
major component of ECM, was measured by quantitativeWestern blot analysis (Fig. 1C). The assay showed that the rel-
ative amount of collagen I was increased in the AF group com-
pared to the SR group (3.44 ± 0.58 vs. 1.62 ± 0.47; P < 0.01)
(Fig. 1D).
To evaluate the changes of local ACE activity during the
AF, we measured the ACE activity in the atrial tissues with
AF and SR by the method of HPLC-based assay (Fig. 2A).
ACE activity was determined by hydrolysis of the synthetic
substrate, HHL and the amount of HA released from the sub-
strate were analyzed. The ACE activity of atrial tissues were
increased in the AF group as compared with that in the SR
group (4.04 ± 0.61 vs. 1.29 ± 0.57 U/mg; P < 0.05) (Fig. 2B).
Relative ERK2 and ACE2 mRNA levels in the left atrial
appendages from the AF group and SR group were measured
and compared by semi-quantitative RT-PCR (Fig. 3A). The
relative amount of ERK2 mRNA in the atrial tissues of the
AF group was greater than that in the SR group (1.14 ± 0.36
vs. 0.38 ± 0.27; P < 0.01) (Fig. 3B). However, the relative
amount of ACE2 mRNA in the AF subjects was less than that
in the SR group (0.48 ± 0.14 vs. 1.00 ± 0.28; P < 0.01)
(Fig. 3C).
Relative protein expression of activated MEK1/2, ERK2,
phosphorylated ERK2, and ACE2 in left atrial appendages
sampled from the AF and SR groups was detected by Western
blotting (Fig. 4A). Activated MEK1/2, an upstream activator
kinase of ERK1/2, was raised in the AF group as compared
with that in the SR group (4.03 ± 0.31 vs. 1.52 ± 0.35;
P < 0.05) (Fig. 4B). Furthermore, phosphorylated and acti-
vated ERK2 in response to activated MEK1/2 can be expected.
The result shows that phosphorylated ERK2 was increased in
the atrial tissue of AF subjects as compared with SR subjects
(3.35 ± 0.97 vs. 0.65 ± 0.04; P < 0.01) (Fig. 4C). Similar to
the protein expression of phosphorylated ERK2, the relative
amount of ERK2 in the AF group was also greater than that
in the SR group (2.59 ± 0.51 vs. 1.16 ± 0.44; P < 0.05)
(Fig. 4D). In contrast, myocardial tissue showed a decrease
in the relative amount of ACE2 (1.20 ± 0.45 vs. 2.75 ± 0.17
in AF vs. SR; P < 0.05) (Fig. 4E).4. Discussion
To our knowledge, our studies demonstrate for the ﬁrst time
that ACE2 contributes to the development of AF in a rapid
pacing-induced model. Our results show that both the mRNA
and protein level of ACE2 are signiﬁcantly downregulated in
the ﬁbrillating atria of pigs.
Numerous studies on human patients and large animal
models suggest the importance of atrial ﬁbrosis in the develop-
Fig. 1. Pathological examination and measurement of collagen I in left atrial appendages of pigs. (A) In ﬁbrillating atria, extensive interstitial ﬁbrosis
was found, as evidenced by Masson’s trichrome stain (original magniﬁcation, 40·; the scale bar represents 100 lm). (B) A higher-power view of (A)
(original magniﬁcation, 200·; the scale bar represents 20 lm). (C) Western blot showing expression of collagen type I. (D) Relative protein expression
of collagen type I in the AF group was signiﬁcantly higher than that in the SR group (P < 0.01) as determined by densitometry of autoradiograms.
The results for each experiment are normalized to the density of b-actin. All values in the histograms are expressed as the means ± S.D.
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atrial myocytes of ﬁbrillating atria in rapid pacing pigs showed
abnormal sarcomeres and a loss of some contractile material
[31]. In the present study, extensive interstitial ﬁbrosis, as evi-
denced by Masson’s trichrome stain, was observed in the atria
with AF (Fig. 1C and D). Classical mechanism of AF was that
AF is caused by single reentry circuit, or triggered by multiple
functional reentrant circuits [38]. However, Nattel [39] has
mentioned that some extrinsic substrates, e.g. atrial ﬁbrosis,
could possibly promote occurrence of single reentry circuit
during progression of AF. No matter how AF begins, atrial
ﬁbrosis alone is enough to promote AF occurrence is proved
in animal model [6].
Several studies have demonstrated that Ang II can stimulate
collagen protein synthesis in cultured cardiac ﬁbroblasts and
increased collagen I mRNA expression in rat hearts [40,41].
Tharaux et al. [42] reported that Ang II activates the expres-
sion of collagen I though the ERK-MAPK signal pathway in
ﬁbrotic tissues. In the present study, the results show that
upregulation of local ACE activity, activation of MEK/
ERK-MAPK cascade and highly expression of collagen I pro-
tein in the atrial tissues with AF. Thus, it can be proposed that
the upregulation of local ACE activity would lead to the raisedAng II levels which could further activate MEK/ERK-MAPK
cascade and stimulate collagen I protein synthesis, which
might explain the highly expression of collagen I protein and
extensive interstitial ﬁbrosis in the ﬁbrillating atria. Goette
et al. [9] has provided the similar results that the expression
of atrial ERK1/ERK2 and ACE is found in patients with
AF and activated ERK1/ERK2 can be reduced in the patients
treated with ACE inhibitors. Dai et al. [43] also demonstrated
that patients with AF show a marked atrial ﬁbrosis and in-
creased expression of ERK1/2 in atrial interstitial cells.
Experimental and clinical data have conﬁrmed the pro-
arrhythmic role of the RAS and demonstrated anti-arrhythmic
eﬀects of ACE inhibitors and AT1 receptor blockers [24,44–
46]. Clinical observations indicate that pharmacological inter-
ventions capable of interfering with electrical and structural
remodeling processes are of critical importance in the manage-
ment of patients with AF [47]. Blockade of the RAS has been
clearly established in the pathophysiology of a number of car-
diac diseases, including hypertension, heart failure, and ven-
tricular remodeling [48]. The beneﬁcial eﬀects of this RAS
blockade may be a consequence of preventing the hypertrophic
and proinﬂammatory actions of Ang II as well as the accumu-
lation of the ECM [49,50]. In addition, Shi et al. [51] reported
Fig. 2. ACE activity was measured with HPLC-based assay in the atrial tissues with AF and SR. (A) The left panel shows the HPLC separation of
HHL hydrolysis catalyzed by ACE in the atrial tissues with SR. Chromatogram of reaction mixtures was showing HHL and HA peaks following
HPLC injection. The right panel shows the generated HA and HHL were resolved and quantiﬁed by HPLC in reaction mixtures from the ﬁbrillating
atria. (B) ACE activities were calculated after HPLC assay and expressed in units per mg of protein. In the AF group (n = 9), ACE activity was higher
than that in the SR group (n = 6) (P < 0.05). Data are expressed as the means ± S.D.
Fig. 3. The relative amounts of ERK2 and ACE2 mRNA in the atrial tissues with AF and SR. (A) Expression of ERK2 and ACE2 in both SR and
AF tissues were determined by RT-PCR. The sizes of the PCR products for ERK2, ACE2 and GAPDH were 622 bp, 412 bp and 413 bp,
respectively. Ampliﬁcation of GAPDH is shown as a control. (B) In the AF group (n = 9), the relative amount of ERK2 mRNA was increased
(P < 0.01) as compared with that of the SR group (n = 6). (C) In contrast with ERK2, the relative amount of ACE2 mRNA was decreased in the AF
group (P < 0.01). The results for each experiment were normalized to the density of the GAPDH PCR product. Histograms of all values are
expressed as the means ± S.D.
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Fig. 4. Protein expression of phosphorylated MEK1/2, ERK2, phosphorylated ERK2, and ACE2 in the atria with AF and SR. (A) Protein
expression in both SR and AF tissues were determined by Western blot using antibodies directed against phosphorylated MEK1/2, ERK2,
phosphorylated ERK2, ACE2, and b-actin. (B) In the AF group (n = 9), the relative expression of phosphorylated MEK1/2 was higher than that in
the SR group (n = 6) (P < 0.05). (C) Phosphorylated ERK2 was signiﬁcantly increased (P < 0.01) in the AF group compared to the SR group. (D)
Total ERK2 was more abundant in the AF group (P < 0.05) compared to the SR group. (E) In the AF group, the level of ACE2 expression was
signiﬁcantly less than that in the SR group (P < 0.05). The results were normalized to the density of b-actin. The values are expressed as the
means ± S.D.
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quency stimulation) are pretreated with an ACE inhibitor to
inhibit the RAS, the ensuing ﬁbrosis in the atrium is markedly
reduced.
A newly discovered enzyme in the RAS pathway, ACE2,
cleaves Ang II to produce the vasodilatory/anti-hypertrophic
peptide Ang 1–7. These data give rise to the hypothesis that
ACE2 provides a counter-regulatory system to Ang II, thereby
contributing to the beneﬁcial eﬀects of the RAS blockade(Fig. 5). The potential role of Ang 1–7 as a cardioprotective
peptide having vasodilator, anti-growth and anti-proliferative
actions has been recognized relatively [19,52]. In addition,
Ang 1–7 can downregulate both transcription and translation
of the AT1 receptor [53]. Ang 1–7 also augments nitric oxide
release, which has a key role in the regulation of cardiac ﬁbro-
sis in response to myocardial ischemia, in part by antagonizing
the action of Ang II [54]. Normal cardiac function in ace/ace2
double-knockout mice suggests that a catalytic product of
Fig. 5. Schematic overview of antagonistic regulation between ACE and ACE2 in the formation of ﬁbrosis during AF formation and sustenance.
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supporting the hypothesis that ACE2 is indeed a critical nega-
tive regulator of the cardiac eﬀects of the RAS [30]. Huentel-
man et al. [55] showed that delivery of Lentivirusal ACE2 to
Sprague–Dawley rat results in signiﬁcant attenuation of the in-
creased heart weight to body weight ratio and myocardial
ﬁbrosis induced by Ang II infusion. These observations dem-
onstrated that ACE2 overexpression is protective for Ang II-
induced cardiac hypertrophy and ﬁbrosis. Our results show
that ACE2 expression is signiﬁcantly downregulated in the
porcine atria with sustained AF, and we suggest that intersti-
tial ﬁbrosis might be due to an imbalance of the RAS caused
by reduced expression of ACE2 during AF development. Re-
cently, Ishiyama et al. [56] provided evidence that the AT1
receptor blockers, losartan and olmesartan, increase Ang pep-
tide concentrations, return AT1 receptor expression to normal,
and increase ACE2 expression in hearts suﬀering from myocar-
dial infarction. These results argue that AT1 receptor blockade
may upregulate ACE2 expression. Thus, we suggest that
decreasing ACE2 expression during AF may aﬀect the Ang
II-dependent signaling pathway.
We propose that there are at least three potential mecha-
nisms by which ACE2 may be cardioprotective via the preven-
tion of cardiac ﬁbrotic processes during AF: ﬁrst, Ang II is
cleaved to Ang 1–7 by ACE2, thereby attenuating Ang II-in-
duced cardiac ﬁbrosis; second, Ang 1–7 may reduce the eﬀects
of Ang II by downregulating expression of AT1 receptor; and
third, the vasodilatory eﬀect of Ang 1–7 might against the
strong vasoconstriction eﬀect of Ang II overproduction during
AF to reduce long-term myocardial ischemia-induced cardiac
ﬁbrosis.
In conclusion, both ACE2 mRNA and protein are downreg-
ulated in the porcine induced by atrial rapid pacing. Our re-
sults reveal that decreased ACE2 level might be associated
with ﬁbrotic formation during AF. The signiﬁcant upregula-
tion of MEK1/2 and ERK2 in the atria with AF conﬁrms pre-
vious observations linking ERK2 expression and AF, and
supports the idea that MEK/ERK-MAPK pathway is acti-vated by the Ang II-signaling pathway. The data further sug-
gest that upregulation of ACE2, which increases the
conversion of Ang II to Ang 1–7 to counterbalance the eﬀects
of ACE, may be a potential therapeutic strategy for AF.
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